Dianthus Therapeutics (DNTH) Shares Outstanding (Weighted Average) (2017 - 2025)

Dianthus Therapeutics has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $36.5 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $36.5 million for Q3 2025, up 6.54% from a year ago — trailing twelve months through Sep 2025 was $36.5 million (up 6.54% YoY), and the annual figure for FY2024 was $33.3 million, up 546.44%.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $36.5 million at Dianthus Therapeutics, up from $35.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for DNTH hit a ceiling of $60.6 million in Q2 2023 and a floor of $874709.0 in Q1 2023.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $34.2 million (2024), compared with a mean of $31.9 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 98.51% in 2023 and later soared 2834.17% in 2024.
  • Dianthus Therapeutics' Shares Outstanding (Weighted Average) stood at $875279.0 in 2022, then skyrocketed by 488.77% to $5.2 million in 2023, then soared by 546.44% to $33.3 million in 2024, then grew by 9.49% to $36.5 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $36.5 million (Q3 2025), $35.8 million (Q2 2025), and $35.8 million (Q1 2025) per Business Quant data.